CEVEC Pharmaceuticals GmbH
CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies
DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance
CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies
02.02.2021 / 14:00
The issuer is solely responsible for the content of this announcement.
CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies
CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
08.01.2021 / 12:00
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA
(R) in gene therapy
(R) Technology for manufacturing of gene therapy products
ELEVECTA
Cologne, Germany, January 8, 2021
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC s proprietary ELEVECTA
(R) Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.